ACY1 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant ACY1.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, IF, IP |
---|---|
Primary Accession | Q03154 |
Other Accession | BC000545 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG1 kappa |
Clone Names | 4F1-B7 |
Calculated MW | 45885 Da |
Gene ID | 95 |
---|---|
Other Names | Aminoacylase-1, ACY-1, N-acyl-L-amino-acid amidohydrolase, ACY1 |
Target/Specificity | ACY1 (AAH00545, 1 a.a. ~ 408 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | ACY1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Aminoacylase-1 is a cytosolic, homodimeric, zinc-binding enzyme that catalyzes the hydrolysis of acylated L-amino acids to L-amino acids and acyl group, and has been postulated to function in the catabolism and salvage of acylated amino acids. ACY1 has been assigned to chromosome 3p21.1, a region reduced to homozygosity in small-cell lung cancer (SCLC), and its expression has been reported to be reduced or undetectable in SCLC cell lines and tumors. The amino acid sequence of human aminoacylase-1 is highly homologous to the porcine counterpart, and ACY1 is the first member of a new family of zinc-binding enzymes.
References
1.Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers.Jansen FH, Rijswijk A, Teubel W, Weerden WM, Reneman S, Bemd GJ, Roobol MJ, Bangma CH, Staal FJ, Jenster G.J Proteome Res. 2011 Dec 2.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.